Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$171000.0.

  • Entrada Therapeutics' Capital Expenditures fell 12676.06% to -$171000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 4618.46%. This contributed to the annual value of $3.2 million for FY2024, which is 4374.78% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Capital Expenditures stood at -$171000.0, which was down 12676.06% from $275000.0 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Capital Expenditures registered a high of $1.7 million during Q1 2023, and its lowest value of -$171000.0 during Q3 2025.
  • Its 4-year average for Capital Expenditures is $860466.7, with a median of $810000.0 in 2022.
  • In the last 5 years, Entrada Therapeutics' Capital Expenditures skyrocketed by 18080.81% in 2023 and then tumbled by 12676.06% in 2025.
  • Entrada Therapeutics' Capital Expenditures (Quarter) stood at $708000.0 in 2022, then surged by 37.85% to $976000.0 in 2023, then tumbled by 34.94% to $635000.0 in 2024, then plummeted by 126.93% to -$171000.0 in 2025.
  • Its Capital Expenditures was -$171000.0 in Q3 2025, compared to $275000.0 in Q2 2025 and $1.1 million in Q1 2025.